Rexahn Pharmaceuticals, Inc. (RNN) Receives FDA Approval for Phase II Clinical Trial of Serdaxin™ for Major Depressive Disorders
Source: http://Blog.QualityStocks.net/?p=12349Posted on Saturday, September 13th, 2008 | In Small & Micro Cap
Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a leader in innovative therapeutics for life-threatening and life-debilitating diseases, recently announced that the company has received FDA approval to begin Phase II trials for Serdaxin™, for the treatment of major depressive disorders. Serdaxin is being developed as an orally administered, extended-release tablet for the treatment of depression and anxiety.
According to the World Health Organization, major depressive disorder is the leading cause of disability in the United States for ages 15 to 44. There are 154 million cases of depression reported worldwide each year, and this condition is nearly twice as prevalent in women as in men. Major depressive disorder is expected to become the second-leading cause of disability worldwide by the year 2020.
Serdaxin is a dual enhancer of serotonin and dopamine neurotransmitters. In preclinical studies, Serdaxin was shown to significantly improve an individual’s negative mood state and the loss of positive mood state, with the onset of action taking less than 48 hours. Serdaxin has shown no serious side effects, cognitive deficit or motor impairment. The Serdaxin Phase II trial is a randomized, double-blind, placebo-controlled parallel study for the treatment of major depressive disorders (MDD). It is a multi-center trial with preliminary data in humans expected in the second half of 2009.
Let us hear your thoughts below:
Last 5 posts by QualityStocks
- Lion Energy, Southern Star Energy (SSEY.OB), Gold Star Resources Fuse to Create Combined Company with Promising Growth Opportunities - November 6th, 2009
- VIASPACE, Inc. (VSPC.OB) Subsidiary Ionfinity Captivates Mass Spectrometry Market - November 6th, 2009
- Google’s Android Takes a Bite Out of Apple - November 6th, 2009
- Continucare Corp. (CNU) First Quarter Fiscal Year 2010 Results Show 116% Increase in Operating Profit - November 6th, 2009
- Muscle Flex, Inc. (MFLI.PK) Now Accepting Orders for the Beagle StepFit, the BUDDY Tablet Caddy and “Danny Alex Commercial Blue” T-Shirts - November 6th, 2009
Depression, Depressive Disorders, Fda, major depressive disorder, Major Depressive Disorders, Rexahn Pharmaceuticals Inc., Small & Micro Cap, treatment of depression, treatment of major depressive disorders, United States, World Health Organization
 About QualityStocks (http://QualityStocks.net)
Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. We believe strong management and vision for the future are crucial for any company to be successful. Timing is everything and we help investors succeed by providing an objective, broad-based view of the SmallCap markets on a daily basis. Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.